talactoferrin alfa

03/01/2013 - "A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis."
09/01/2015 - "Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial."
09/01/2015 - "Administration of oral talactoferrin was not associated with reduced 28-day mortality in patients with severe sepsis and may even be harmful."
09/01/2015 - "This phase II/III clinical trial compared talactoferrin with placebo, in addition to standard of care, in patients with severe sepsis. "
03/01/2013 - "Enteral administration of talactoferrin reduced 28-day all-cause mortality in patients with severe sepsis. "

07/01/2012 - "However, ongoing phase 3 trials are assessing melanoma-associated antigen A3 vaccine, liposomal BLP25, belagenpumatucel-L, and talactoferrin. "
10/01/2012 - "Ipilimumab, antibody to Programmed death-1 (PD-1), Toll-like receptor agonists, liposomal BLP25 (L- BLP25), belagenpumatucel-L, melanoma-associated antigen A3 (MAGE-A3) vaccine and talactoferrin have been proved to be effective for lung cancer through early clinical trials, most of the drugs have moved forward to phase III trials, so as to collect much higher level evidence to support the immunotherapies incorporated into the multidisciplinary treatment of lung cancer. "

10/01/2008 - "Based on this data, talactoferrin was subsequently tested clinically in a Phase II trial in patients with diabetic ulcers and was found to be effective and safe. "
10/01/2008 - "Talactoferrin should be further evaluated in patients with diabetic and other types of ulcers."
01/01/2007 - "Topical talactoferrin appears to be safe and well tolerated and improves healing of diabetic neuropathic ulcers."
01/01/2007 - "In phase 1, groups of 3 patients each received open-label 1%, 2.5%, or 8.5% talactoferrin gel twice daily, in a sequential design, to their ulcer for 30 days. "
01/01/2007 - "Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study."

01/01/2018 - "Talactoferrin alpha is a promising non-toxic solid tumor cancer agent that met with success in the treatment of early-stage lung cancer clinically in humans. "
03/01/2009 - "Belagenpumatucel-L is a nonspecific allogeneic vaccine derived from multiple lung cancer cell lines, and the agent talactoferrin alfa might improve clinical outcomes based on broad immune system activation and stimulation. "
10/01/2012 - "Ipilimumab, antibody to Programmed death-1 (PD-1), Toll-like receptor agonists, liposomal BLP25 (L- BLP25), belagenpumatucel-L, melanoma-associated antigen A3 (MAGE-A3) vaccine and talactoferrin have been proved to be effective for lung cancer through early clinical trials, most of the drugs have moved forward to phase III trials, so as to collect much higher level evidence to support the immunotherapies incorporated into the multidisciplinary treatment of lung cancer. "

01/01/2016 - "To evaluate the safety and explore the efficacy of recombinant human lactoferrin (talactoferrin [TLf]) to reduce infection. "